Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833559 | 0.89 | EPHX2 (0.39) | EPHX2THRBATML3MBTL1KDM4E | |
| SCHEMBL3827038 | 0.89 | EPHX2 (0.39) | EPHX2THRBATML3MBTL1KDM4E | |
| SCHEMBL18115895 | 0.89 | EPHX2 (0.39) | EPHX2THRBATML3MBTL1KDM4E | |
| SCHEMBL10938895 | 0.84 | EPHX2 (0.53) | EPHX2THRBATML3MBTL1EPHX1 | |
| SCHEMBL19240735 | 0.82 | EPHX2 (0.60) | EPHX2EPHX1 | |
| SCHEMBL27786470 | 0.82 | EPHX2 (0.40) | EPHX2THRBATML3MBTL1KDM4E | |
| SCHEMBL6418827 | 0.81 | OPRK1 (0.49) | EPHX2KDM4EEPHX1NPY2R | |
| SCHEMBL6414021 | 0.80 | EPHX2 (0.50) | EPHX2KDM4ECHRM2CHRM5CHRM3 | |
| SCHEMBL12750515 | 0.79 | MAPT (0.53) | EPHX2THRBATML3MBTL1KMT2A | |
| SCHEMBL8367374 | 0.79 | THRB (0.66) | THRBATML3MBTL1KDM4ECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-3331869-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| CN-103097354-A | Substituted benzamide compounds | GRUENENTHAL CHEMIE | 2013-05-08 | — | — | CN | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004111003-A1 | AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | EPHX2 1291/4885THRB 1389/4885ATM 4472/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | EPHX2 2516/4885THRB 3934/4885ATM 3327/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | EPHX2 1475/4885THRB 507/4885ATM 1662/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | EPHX2 2516/4885THRB 3934/4885ATM 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.